AI @ Pfizer

Comprehensive analysis confirms Pfizer’s dominance in embedding AI and ML throughout research, development, marketing, compliance, and consumer engagement, reinforcing a mature, integrated AI strategy fueling pharma innovation.

• Klover.ai: Pfizer's AI Strategy: Analysis of Dominance in Pharma

Expansion of AI-powered drug discovery collaboration with XtalPi using its XFEP platform to enhance Pfizer's small molecule discovery; evidence of real-time AI agent techniques emerging within pharma digital innovation.

• Fierce Biotech: Pfizer expands XtalPi small-molecule discovery collaboration
• PR Newswire: XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations

Introduction of a generative AI-powered consumer digital product answering health questions; expansion of AI partnership with PostEra on generative chemistry for small molecule and antibody-drug conjugate design, surpassing preclinical milestones 40% faster than expected; $350M investment in AI for molecule design confirmed.

• Pfizer: A New Consumer Digital Product Providing Answers You Can Trust
• C&EN: Pfizer doubles down on AI partnership with antibody-drug startup PostEra

Pfizer demonstrates leadership in AI drug discovery, cutting development time, personalizing medicine, and reducing clinical trial failure; reporting 12% clinical trial failure reduction through AI; partnerships with Tempus and internal ML Research Hub emphasize end-to-end AI pipeline.

• Virtasant: Pfizer's AI Drug Discovery Cuts Years Off Development Time

Appointment of Berta Rodriguez-Hervas as Chief AI and Analytics Officer to drive AI strategy; continuing evidence of AI aiding accelerated drug market entry.

• Technology Magazine: New AI Chief at Pfizer to Boost Digital Innovation

Pfizer collaborates with CeMM on novel AI-driven platforms for small molecule-protein interaction mapping accelerating drug discovery; recognized as an industry AI leader by physicians; active deployment of compliance AI copilots.

• Fierce Biotech: Pfizer collab with CeMM leads to new drug discovery AI platform

Launch of 'Charlie', Pfizer's customized generative AI platform integrated with NLP and recommendation engines, multiplying content creation output by up to 5x and accelerating marketing approvals by 2-3x; exploration of AI in clinical trial data oversight.

• Digiday: With 'Charlie,' Pfizer is building a new generative AI platform for pharma marketing
• PharmiWeb: How Pfizer is Revolutionising Pharma Marketing with AI

Pfizer employs generative AI across approximately 17 use cases, including scientific research and marketing; establishes an official AI policy position emphasizing responsible use.

• CIO.inc: How Gen AI Is Helping Pfizer Change Healthcare Narrative
• Pfizer: Policy Position on Artificial Intelligence

Rapid scale-up of AI/ML efforts announced, aimed at bringing transformative medicines to market faster through collaborative initiatives.

• BioSpace: Pfizer Doubles Down on AI/ML to Bring Transformative Medicines to Patients

Detailed analysis of three AI use cases at Pfizer highlighted how AI supports immediate business objectives in pharmaceutical development.

• Emerj Artificial Intelligence Research: Artificial Intelligence at Pfizer - 3 Use Cases

Pfizer formally communicates how AI and supercomputing shorten timelines for new vaccine and medicine development.

• Pfizer Insights: Pfizer Is Using AI to Discover Breakthrough Medicines

Early AI exploration with a collaboration involving IBM Watson's machine learning and natural language processing to augment Pfizer's pharma research capabilities.

• BioPharma Dive: Pharma and AI? Let's try augmented intelligence first